Your AI-Trained Oncology Knowledge Connection!

Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma : Episode 3

Video

January 23, 2023

Defining Frailty in Multiple Myeloma for Optimal Treatment

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Now Viewing

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP: 14.Targets in Multiple Myeloma: GPRC5D

EP: 15.Targets in Multiple Myeloma: FcRH5

EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment

EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity

Latest Conference Coverage

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP: 14.Targets in Multiple Myeloma: GPRC5D

EP: 15.Targets in Multiple Myeloma: FcRH5

EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment

EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care

Newsletter

Latest CME

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

Latest Conference Coverage